Chemokine CXCL10 at week 4 of treatment predicts sustained virological response in patients with chronic hepatitis C - PubMed (original) (raw)

Chemokine CXCL10 at week 4 of treatment predicts sustained virological response in patients with chronic hepatitis C

Ivan Kurelac et al. J Interferon Cytokine Res. 2012 Aug.

Abstract

The aim of this study was to analyze the predictive value of CXCL9, CXCL10, and CXCL11 concentrations before and after 4 and 12 weeks of treatment with pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C infected with the hepatitis C virus genotype 1. The study included 46 adult patients (29 women and 17 men). Chemokine quantification in the serum was performed at baseline and after 1, 3, and 6 months of treatment by enzyme immunoassay. Chemokine responses were compared in patients achieving a sustained virological response to treatment (SVR, n=26) and the non-SVR group (n=20). The differences in the CXCL9 and CXCL10 concentrations between the SVR and non-SVR groups were statistically significant. A multivariant analysis showed a significant association between treatment failure and higher concentrations of CXCL10. A higher predictive value of CXCL10 concentrations after 4 weeks of treatment compared to pretreatment values has been found (area under the curve 0.9288 and 0.7942, respectively, P=0.016). CXCL10 concentrations above 250 pg/mL 4 weeks after the start of treatment were independently associated with non-SVR. In conclusion, the results of this study have shown that CXCL10 concentrations at the time of a rapid viral response (4 weeks) are better predictors of achieving SVR compared to baseline levels. Additionally, this study suggests an important role of CXCL9 as a biomarker of SVR in patients with chronic hepatitis C.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

(a–c) Concentrations of CXCL9, CXCL10, and CXCL11 in the serum of patients with chronic hepatitis C treated with pegylated interferon alpha 2b and ribavirin based on the virological response.

FIG. 2.

FIG. 2.

Logistic regression analysis assessing the prognostic value of chemokine CXCL10 concentration after 4 weeks of treatment.

Similar articles

Cited by

References

    1. Askarieh G. Alsiö A. Pugnale P. Negro F. Ferrari C. Neumann AU. Pawlotsky JM. Schalm SW. Zeuzem S. Norkrans G. Westin J. Söderholm J. Hellstrand K. Lagging M DITTO-HCV and NORDynamIC Study Groups. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology. 2010;51(5):1523–1530. - PubMed
    1. Butera D. Marukian S. Iwamaye AE. Hembrador E. Chambers TJ. Di Bisceglie AM. Charles ED. Talal AH. Jacobson IM. Rice CM. Dustin LB. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 2005;106(4):1175–1182. - PMC - PubMed
    1. Casrouge A. Decalf J. Ahloulay M. Lababidi C. Mansour H. Vallet-Pichard A. Mallet V. Mottez E. Mapes J. Fontanet A. Pol S. Albert ML. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest. 2011;121(1):308–317. - PMC - PubMed
    1. Charo IF. Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610–621. - PubMed
    1. Diago M. Castellano G. García-Samaniego J. Pérez C. Fernández I. Romero M. Iacono OL. García-Monzón C. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut. 2006;55(3):374–379. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources